Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line.

Zhao G, Guo J, Li D, Jia C, Yin W, Sun R, Lv Z, Cong X.

DNA Cell Biol. 2013 Dec;32(12):699-707. doi: 10.1089/dna.2013.2130. Epub 2013 Sep 19.

2.

LMTK3 escapes tumour suppressor miRNAs via sequestration of DDX5.

Jacob J, Favicchio R, Karimian N, Mehrabi M, Harding V, Castellano L, Stebbing J, Giamas G.

Cancer Lett. 2016 Mar 1;372(1):137-46. doi: 10.1016/j.canlet.2015.12.026. Epub 2015 Dec 29.

PMID:
26739063
3.

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.

Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ.

Breast Cancer Res Treat. 2011 Nov;130(2):663-79. doi: 10.1007/s10549-011-1690-0. Epub 2011 Aug 4.

4.

3,6-Dihydroxyflavone Suppresses Breast Carcinogenesis by Epigenetically Regulating miR-34a and miR-21.

Peng X, Chang H, Gu Y, Chen J, Yi L, Xie Q, Zhu J, Zhang Q, Mi M.

Cancer Prev Res (Phila). 2015 Jun;8(6):509-17. doi: 10.1158/1940-6207.CAPR-14-0357. Epub 2015 Mar 17.

5.

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.

Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME.

Mol Cancer. 2014 Oct 6;13:229. doi: 10.1186/1476-4598-13-229.

6.

microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway.

Cui W, Zhang S, Shan C, Zhou L, Zhou Z.

FEBS J. 2013 Aug;280(16):3962-74. doi: 10.1111/febs.12398. Epub 2013 Jul 10.

7.

MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.

Ma Y, Qin H, Cui Y.

Biochem Biophys Res Commun. 2013 Nov 29;441(4):958-63. doi: 10.1016/j.bbrc.2013.11.010. Epub 2013 Nov 9.

PMID:
24220341
8.

MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression.

Peng Y, Guo JJ, Liu YM, Wu XL.

Biosci Rep. 2014 Jun 25;34(3). pii: e00112. doi: 10.1042/BSR20140020.

9.

Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway.

Liu J, Li Y.

Biochem Biophys Res Commun. 2015 Nov 13;467(2):242-7. doi: 10.1016/j.bbrc.2015.09.182. Epub 2015 Oct 5.

PMID:
26436206
10.

MicroRNA-34a suppresses the breast cancer stem cell-like characteristics by downregulating Notch1 pathway.

Kang L, Mao J, Tao Y, Song B, Ma W, Lu Y, Zhao L, Li J, Yang B, Li L.

Cancer Sci. 2015 Jun;106(6):700-8. doi: 10.1111/cas.12656.

11.

MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1.

Li XJ, Ji MH, Zhong SL, Zha QB, Xu JJ, Zhao JH, Tang JH.

Arch Med Res. 2012 Oct;43(7):514-21. doi: 10.1016/j.arcmed.2012.09.007. Epub 2012 Oct 16.

PMID:
23085450
12.

Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.

Tan S, Ding K, Li R, Zhang W, Li G, Kong X, Qian P, Lobie PE, Zhu T.

Breast Cancer Res. 2014 Apr 15;16(2):R40. doi: 10.1186/bcr3644.

13.

MicroRNA-34a and microRNA-21 play roles in the chemopreventive effects of 3,6-dihydroxyflavone on 1-methyl-1-nitrosourea-induced breast carcinogenesis.

Hui C, Yujie F, Lijia Y, Long Y, Hongxia X, Yong Z, Jundong Z, Qianyong Z, Mantian M.

Breast Cancer Res. 2012 May 22;14(3):R80.

14.

A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.

Zhan Y, Zhang Y, Liu C, Zhang J, Smith WW, Wang N, Chen Y, Zheng L, He L.

Cancer Prev Res (Phila). 2012 Jun;5(6):864-73. doi: 10.1158/1940-6207.CAPR-11-0575. Epub 2012 Apr 11.

15.

High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.

Asano T, Sato S, Yoshimoto N, Endo Y, Hato Y, Dong Y, Takahashi S, Fujii Y, Toyama T.

Jpn J Clin Oncol. 2014 Oct;44(10):889-97. doi: 10.1093/jjco/hyu113. Epub 2014 Aug 27.

16.

MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.

Li L, Yuan L, Luo J, Gao J, Guo J, Xie X.

Clin Exp Med. 2013 May;13(2):109-17. doi: 10.1007/s10238-012-0186-5. Epub 2012 May 24.

PMID:
22623155
17.

Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer.

Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D.

Oncotarget. 2015 Oct 6;6(30):29947-62. doi: 10.18632/oncotarget.4937.

18.

MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.

Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA.

Breast Cancer Res. 2015 Jan 30;17:13. doi: 10.1186/s13058-015-0515-1.

19.

MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.

Cui J, Yang Y, Li H, Leng Y, Qian K, Huang Q, Zhang C, Lu Z, Chen J, Sun T, Wu R, Sun Y, Song H, Wei X, Jing P, Yang X, Zhang C.

Oncogene. 2015 Jul 23;34(30):3895-907. doi: 10.1038/onc.2014.430. Epub 2014 Dec 22. Erratum in: Oncogene. 2015 Jul 23;34(30):4018.

PMID:
25531331
20.

An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.

Xiong J, Yu D, Wei N, Fu H, Cai T, Huang Y, Wu C, Zheng X, Du Q, Lin D, Liang Z.

FEBS J. 2010 Apr;277(7):1684-94. doi: 10.1111/j.1742-4658.2010.07594.x. Epub 2010 Feb 17.

Items per page

Supplemental Content

Write to the Help Desk